


Senores Pharmaceuticals begins operations at greenfield API facility in Mehsana

28 February 2025 | News

This is Senores' second API manufacturing facility, adding significantly to existing manufacturing capabilities



Senores Pharmaceuticals Limited has inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Mehsana, Gujarat.

Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility, adding significantly to the existing API manufacturing capabilities.

Commenting on the inauguration, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the Regulated Markets, especially in the CDMO/CMO business."

Recently, Senores also acquired the USFDA-approved Abbreviated New Drug Application ('ANDA') for Roflumilast 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc., strengthening its presence in the US generic pharmaceutical market. The acquisition, funded through the IPO proceeds, aligns with the company's strategic growth initiatives.

The companies' current portfolio includes 24 ANDA and 21 CMO/CDMO commercial products that are permitted for distribution in the USA.

Senores has 2 manufacturing facilities for formulations— one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda.

Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).